NLS Pharmaceutics (NLSP) Competitors $1.30 -0.23 (-15.03%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$1.42 +0.12 (+9.23%) As of 03/28/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. PMN, MIRA, LIAN, NNVC, CVM, CGTX, LSTA, LPCN, ME, and CLDIShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include ProMIS Neurosciences (PMN), MIRA Pharmaceuticals (MIRA), LianBio (LIAN), NanoViricides (NNVC), CEL-SCI (CVM), Cognition Therapeutics (CGTX), Lisata Therapeutics (LSTA), Lipocine (LPCN), 23andMe (ME), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. ProMIS Neurosciences MIRA Pharmaceuticals LianBio NanoViricides CEL-SCI Cognition Therapeutics Lisata Therapeutics Lipocine 23andMe Calidi Biotherapeutics ProMIS Neurosciences (NASDAQ:PMN) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk. Does the MarketBeat Community believe in PMN or NLSP? NLS Pharmaceutics received 5 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformProMIS NeurosciencesOutperform Votes3100.00% Underperform VotesNo VotesNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Does the media prefer PMN or NLSP? In the previous week, ProMIS Neurosciences had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 3 mentions for ProMIS Neurosciences and 2 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.43 beat ProMIS Neurosciences' score of 0.30 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Overall Sentiment ProMIS Neurosciences Neutral NLS Pharmaceutics Positive Do analysts recommend PMN or NLSP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProMIS Neurosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PMN or NLSP more profitable? NLS Pharmaceutics' return on equity of 0.00% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets ProMIS NeurosciencesN/A -636.20% -130.32% NLS Pharmaceutics N/A N/A N/A Which has stronger earnings & valuation, PMN or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProMIS NeurosciencesN/AN/A-$13.21M-$0.10-7.25NLS PharmaceuticsN/AN/A-$12.17MN/AN/A Do insiders and institutionals have more ownership in PMN or NLSP? 50.1% of ProMIS Neurosciences shares are held by institutional investors. 4.4% of ProMIS Neurosciences shares are held by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, PMN or NLSP? ProMIS Neurosciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.3, suggesting that its share price is 130% less volatile than the S&P 500. SummaryProMIS Neurosciences and NLS Pharmaceutics tied by winning 6 of the 12 factors compared between the two stocks. Remove Ads Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.68M$6.90B$5.64B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E RatioN/A7.1723.4318.71Price / SalesN/A218.12387.6790.64Price / CashN/A65.6738.1734.64Price / BookN/A6.386.894.23Net Income-$12.17M$142.12M$3.20B$247.34M7 Day Performance-13.91%-5.15%-3.04%-2.28%1 Month Performance-29.35%-7.55%1.53%-5.80%1 Year Performance622.22%-11.06%9.36%-0.94% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.30-15.0%N/A+622.2%$4.68MN/A0.006Short Interest ↓PMNProMIS Neurosciences0.707 of 5 stars$0.65+1.5%N/A-62.0%$21.25MN/A-6.505Short Interest ↑Gap UpMIRAMIRA Pharmaceuticals1.9682 of 5 stars$1.23-3.9%$14.00+1,038.2%-3.6%$21.20MN/A-2.202Earnings ReportShort Interest ↑LIANLianBioN/A$0.20-2.3%N/A-41.2%$21.12MN/A-0.24110Gap DownNNVCNanoViricidesN/A$1.33+2.3%N/A+4.3%$20.80MN/A-1.8520News CoverageCVMCEL-SCIN/A$0.27+2.4%N/A-87.5%$20.56MN/A-0.5543Analyst ForecastHigh Trading VolumeCGTXCognition Therapeutics3.7383 of 5 stars$0.49+7.7%$7.50+1,431.2%-77.2%$20.35MN/A-0.5020Short Interest ↓Analyst RevisionGap UpLSTALisata Therapeutics3.0201 of 5 stars$2.33-2.1%$15.00+543.8%-24.7%$20.09M$1M-0.9330Short Interest ↓Gap DownLPCNLipocine2.075 of 5 stars$3.68+4.0%$10.00+171.7%-36.9%$19.69M$11.20M-4.8410ME23andMe1.2364 of 5 stars$0.73-59.2%$9.40+1,187.7%-94.3%$19.58M$208.78M-0.05770Options VolumeNews CoverageGap DownHigh Trading VolumeCLDICalidi Biotherapeutics2.204 of 5 stars$0.73-1.9%$15.00+1,966.4%N/A$19.21M$50,000.000.0038News CoverageGap Down Remove Ads Related Companies and Tools Related Companies ProMIS Neurosciences Alternatives MIRA Pharmaceuticals Alternatives LianBio Alternatives NanoViricides Alternatives CEL-SCI Alternatives Cognition Therapeutics Alternatives Lisata Therapeutics Alternatives Lipocine Alternatives 23andMe Alternatives Calidi Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NLSP Stock Free NLSP Stock Alerts